• 1
    Bioscience Division, Los Alamos National Laboratory, the Regents of the University of California. HPV sequence database: PV types and hosts [database online]. Available from URL:
  • 2
    Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796802.
  • 3
    Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press, 1997.
  • 4
    Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; 31: 313.
  • 5
    Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002; 186: 13961402.
  • 6
    Bernard HU. Coevolution of papillomaviruses with human populations. Trends Microbiol. 1994; 2: 140143.
  • 7
    Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287: 21202129.
  • 8
    Monk BJ, Brewster WR. Does the ALTS trial apply to the community-based practitioner? Am J Obstet Gynecol. 2003; 188: 13811382.
  • 9
    Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002; 288: 17491757.
  • 10
    ACOG Committee on Practice Bulletins. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August, 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003; 102: 417427.
  • 11
    Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342362.
  • 12
    Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001; 285: 31073115.
  • 13
    Chan JK, Monk BJ, Brewer C, et al. HPV infection and number of lifetime sexual partners are strong predictors for “natural” regression of CIN 2 and 3. Br J Cancer. 2003; 89: 10621066.
  • 14
    Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 16451651.
  • 15
    Im S, Monk BJ, Villarreal LP. Prevention of cervical cancer with vaccines. Curr Oncol Rep. 2001; 3: 322328.
  • 16
    Guyot A, Karim S, Kyi MS, Fox J. Evaluation of adjunctive HPV testing by Hybrid Capture II® in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infect Dis. 2003; 3: 23.
  • 17
    Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000; 92: 464474.
  • 18
    Ramirez JE, Ramos DM, Clayton L, Kanowitz S, Moscicki AB. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health. 1997; 6: 113121.
  • 19
    Anhang R, Stryker JE, Wright TC, Goldie SJ. News media coverage of human papillomavirus. Cancer. 2004; 100: xxxxxx.
  • 20
    Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer. 2002; 95: 21452151.